Vice Chairman, Department of Neurology; Director, Movement Disorders Program; Medical Director, Georgetown University Hospital National Parkinsonism Foundation Center of Excellence; Medical Director, Translational Neurotherapeutics Program; Associate Professor, Department of Neurology, Georgetown University
Treatment Options for Advanced Parkinson Disease
April 25th 2025Panelists discuss how alternative formulations and administration routes like Levodopa/carbidopa intestinal gel and deep brain stimulation have impacted advanced Parkinson disease management, including which patient populations benefit most and when these options are recommended.
Patient Perspectives and Expert Tips on Managing CSAI Challenges in PD
April 24th 2025Pagan shared insights from InfusON patient interviews on the challenges and benefits of initiating CSAI therapy and discussed how expert roundtable recommendations can guide neurologists in managing skin nodules associated with treatment.
Excitement Around New Therapeutics in Parkinson Disease
April 21st 2025Pagan discusses the excitement surrounding new therapeutics in neurodegenerative diseases and how advances in protein clearance and inflammation reduction could lead to disease-modifying treatments for conditions like Parkinson disease.
Real-World Impact of CSAI on Motor Fluctuations in PD
April 21st 2025Fernando L. Pagan, MD, discussed how continuous subcutaneous apomorphine infusion impacts long-term motor fluctuations in Parkinson disease, highlighting InfusON extension study findings on uninterrupted "good ON" time and reduced "OFF" periods as evidence of its real-world efficacy.
Unmet Needs and Improving Diagnosis of Dyskinesia in Parkinson Disease
The expert panel reviews unmet needs in treatment and management of dyskinesia and shares advice for physicians treating patients with Parkinson disease.
Surgical Options and Emerging Treatments for Parkinson Disease
Drs Fernando Pagan, Robert A. Hauser, and Daniel Kremens highlight existing and emerging surgical and pharmacological options for treatment of dyskinesia in Parkinson disease.
Use of Other Amantadine Formulations in Parkinson Disease
The expert neurology panel shares their clinical experience with different formulations of amantadine in management of dyskinesia in patients with Parkinson disease.
Amantadine DR/ER for Dyskinesia in Parkinson Disease: Safety Profile and Ideal Patient
The expert panel reviews the safety profile of amantadine DR/ER and who may be an ideal patient for its use in patients with Parkinson disease experiencing dyskinesia.
Studies With Amantadine-DR/ER for Treatment of Dyskinesia
The expert neurology panel discusses clinical trial data of amantadine-DR/ER in treatment of dyskinesia and OFF episodes in Parkinson disease.
Amantadine Formulations in Treatment of Dyskinesia in Parkinson Disease
Drs William G. Ondo and Rajesh Pahwa analyze the pharmacokinetics of different formulations of amantadine for treatment of dyskinesia in Parkinson disease.
Promising Disease-Modifying Therapies in Parkinson Disease
Despite years of use of gold-standard therapy levodopa, therapeutic development in Parkinson disease has advanced rapidly and expanded to numerous novel pathways and targets.
Treatment of Dyskinesia in Patients with Parkinson’s Disease
Drs Rajesh Pahwa, Daniels Kremens and Fernando Pagan provide an overview of current treatment options for treatment of dyskinesia in patients with Parkinson’s Disease.
Challenges in Balancing Treatment of OFF Episodes and Dyskinesia in Parkinson Disease
The expert panel highlights challenges in treatment of OFF episodes and dyskinesia together and long-term consequences of delaying treatment for dyskinesia in patients with Parkinson disease.
Diagnosis of Dyskinesia and Impact on Quality of Life of Patients With Parkinson Disease
The expert panel shares strategies for accurate clinical diagnosis of dyskinesia in patients with Parkinson disease and discusses how dyskinesia may impact the quality of life.
Pathophysiology of Dyskinesia in Parkinson Disease
Drs William G. Ondo and Robert A. Hauser discuss the understanding of pathophysiology and clinical features of dyskinesia in patients with Parkinson disease.
Challenges With Parkinson Disease Treatments
Drs Rajesh Pahwa and Daniel E. Kremens discuss challenges with Parkinson disease treatment and management of motor fluctuations, dyskinesia and OFF episodes in patients.
Use of Parkinson Disease Treatments and Identification of OFF Episodes in Clinical Practice
The expert panel discusses advances in formulations of carbidopa/levodopa and identification of OFF and ON time in patients with Parkinson disease.